The MassBioDrive program will host two cohorts in 2025, though each will focus on a different segment of the industry. Because of this, scientific founders or emerging biotech companies should apply for the Spring 2025 (S25) biotech cohort, which is now open for applications. The Fall 2025 (F25) cohort will be exclusively for techbio startups working to support drug discovery and development, and that application will open in May. Both cohorts will participate in MassBioDrive’s tailored program of business fundamental curriculum, mentorship, industry connections, and resources.
- S25 Application close: January 17, 2025 at 5:00 PM ET
- S25 cohort: March 17 – May 9, 2025
‘Techbio’ gets the Drive treatment: Recognizing the growing role that techbio—by one definition, companies leveraging data and technology to improve, enhance, and accelerate life sciences processes—has in the life sciences, MassBio is establishing a tailored Drive program specifically focused on helping founders and emerging techbio startups develop a strong business foundation and connect with key stakeholders earlier in their growth trajectory.
- A priority initiative within the MassBio Vision 2030 strategic plan is to infuse awareness of artificial intelligence and machine learning (AI/ML) and other technologies into foundational MassBio programs.
- Previously, MassBio has elevated techbio startups through its Align Summit, where half of the 50 companies invited to present at the early-stage and funder partnering conference were operating in the AI/Ml for drug discovery and development space.
New eligibility criteria: The limit for equity-based funding raised for Drive companies has been increased to $1.5 million, a recognition of the changing funding environment and the creative ways that pre-seed and seed-stage companies are raising dollars.
What we’re saying:
- “Our MassBio Vision 2030 strategic plan makes it clear that supporting and growing seed and early-stage biotechs in Massachusetts remains a top priority and we do that by improving access to capital, expertise, and other resources,” said MassBio CEO & President Kendalle Burlin O’Connell. “The most direct way that MassBio can do this is through MassBioDrive, and we’re excited to expand not only operational support but cash as well and welcome techbio companies into the Drive community.”
- “Massachusetts is a prime location for ‘techbio’ to mature and for AI in drug discovery and research to thrive,” added MassBio Chief Innovation and Operating Officer Jason Cordeiro. “We have a remarkable opportunity to facilitate collaboration and turbocharge the role AI, cloud computing, and advanced analytics play in delivering new treatments to patients.”
Drive’s history: Launched in 2022, MassBioDrive’s mission is to advance breakthrough science while providing opportunities to innovators from all parts of the life sciences ecosystem. Over its first six cohorts, MassBioDrive accelerated 31 companies that have raised $14M post-program. In the fall of 2023, MassBio and SCBio partnered on the first expansion of the Drive program.
The programming: MassBioDrive provides each company with a market-focused launchpad of training, resources, and networks in their growth trajectory to fully realize the potential of their science – at no cost and with no equity taken. During a high-impact, eight-week hybrid program, the five startups selected through a rigorous vetting process will:
- Participate in six business-focused curriculum modules taught by seasoned experts from Browne Consulting (Business Fundamentals), Thermo Fisher Scientific (Drug Development), Wilson Sonsini Goodrich & Rosati (IP and Legal), Xontogeny (Fundraising), and other industry leaders;
- Partner with a dedicated group of industry mentors;
- Connect with MassBio’s global life sciences network through ecosystem-wide events and targeted 1:1 pitch opportunities; and
- After presenting at a Demo Day during the MassBio Align Summit in October, receive a stipend award from Bristol Myers Squibb and access to and/or resources from MassBioDrive partners including Evaluate and Google Cloud.